Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Suven Life Sciences Limited
Press Release Feb 06 2024
Business
Feb 6 2024
5 min read

Press Release Feb 06 2024

Suven Life Sciences Limited has informed the Exchange regarding a press release dated February 06, 2024, titled "Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder study in USA".

View Attachment